4.4 Review

Controversies in the Therapy of Low-Grade Gliomas

Journal

CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 20, Issue 4, Pages -

Publisher

SPRINGER
DOI: 10.1007/s11864-019-0625-6

Keywords

Low-grade glioma; Controversy; PCV; Temozolomide; IDH mutation

Categories

Ask authors/readers for more resources

Opinion statementIn the context of the new WHO classification system, all low-grade gliomas must have an IDH mutation, with or without 1p/19q codeletion. Upon discovery of the tumor, maximal safe surgical resection is the most appropriate first step due to the current inability to differentiate between IDH mutant and IDH wild-type tumors by imaging alone. In the postoperative setting, based on the synthesis and interpretation of the available data, we recommend utilizing conventional radiation therapy and PCV in all high-risk-low-grade gliomas. For patients felt to be in a low risk category, we recommend maintaining a low threshold to initiate treatment. In the setting of tumor recurrence, consideration of all treatment options is reasonable, but treatment with alkylator therapy has the strongest supporting data.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available